Kura Oncology to Report Third Quarter 2022 Financial Results  

Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) will report its third quarter 2022 financial results before U.S. markets open on November 3, 2022. Management will host a conference call at 8:00 a.m. ET to discuss the results and provide a corporate update. Kura is focused on precision medicines for cancer treatment, with a pipeline including Ziftomenib, currently in trials for acute myeloid leukemia, and Tipifarnib, which has Breakthrough Therapy Designation for HRAS mutant head and neck cancer. A live webcast will also be available for investors.

Positive

• Kura's Ziftomenib is in Phase 1b trials for acute myeloid leukemia, indicating active clinical research.
• Tipifarnib has received Breakthrough Therapy Designation for HRAS mutant head and neck squamous cell carcinoma, enhancing its market potential.
• Kura is advancing several clinical trials, expanding its drug pipeline and potential revenue sources.

Negative

• No negative aspects reported. Potential concerns include the inherent risks in clinical trials and future regulatory approvals.

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2022 financial results before U.S. financial markets open on Thursday, November 3, 2022. Kura’s management will host a webcast and conference call at 8:00 a.m. ET / 5:00 a.m. PT that day to discuss the financial results and provide a corporate update. 

To participate in the teleconference, domestic callers should dial 1-888-394-8218 and international callers should dial 1-323-994-2093 and reference conference ID: 2251807. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1576867&tp_key=fe0ec98bea. A replay of the webcast will be available online from the investor relations section of the company website at www.kuraoncology.com.

About Kura Oncology 

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib (KO-539), a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed/refractory acute myeloid leukemia, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI), has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) and is currently in a registration-directed trial (AIM-HN) in patients with this devastating disease. In addition, Kura is conducting a Phase 1/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3Kα inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3Kα pathways. The Company is also preparing to initiate a Phase 1 trial (KURRENT-LUNG) of tipifarnib in combination with osimertinib in treatment-naïve locally advanced/metastatic EGFR mutated non-small cell lung cancer. Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Company’s next-generation FTI, through IND-enabling studies. For additional information, please visit Kura’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Senior Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
ICR Westwicke
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

When will Kura Oncology report its third quarter 2022 financial results?

Kura Oncology will report its third quarter 2022 financial results on November 3, 2022, before U.S. markets open.

What time is the Kura Oncology conference call for financial results?

The conference call for Kura Oncology's financial results will take place at 8:00 a.m. ET on November 3, 2022.

What is the primary focus of Kura Oncology?

Kura Oncology focuses on precision medicines for cancer treatment, specifically developing small molecule drug candidates.

What clinical trials is Kura Oncology currently conducting?

Kura is conducting clinical trials for Ziftomenib, Tipifarnib, and planning additional studies for their next-generation drug KO-2806.

What is the significance of the Breakthrough Therapy Designation for Tipifarnib?

The Breakthrough Therapy Designation for Tipifarnib enhances its development and potential market approval for HRAS mutant head and neck cancer.